MedTrace Logo

Ivabradine to Prevent Anthracycline-induced Cardiotoxicity

NCT04030546 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2019-12-18

No results posted yet for this study

Summary

The aim of this study is to investigate protective effects of ivabradine in adult cancer patients undergoing anthracycline-based chemotherapy.

Conditions

  • Patients With Cancer

Interventions

DRUG

Ivabradine

Ivabradine capsule

Sponsors & Collaborators

  • Vilnius University

    lead OTHER

Principal Investigators

  • Sigita Aidietiene, MD, PhD · Vilnius University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2020-06-01
Completion
2020-12-31

Countries

  • Lithuania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04030546 on ClinicalTrials.gov